Physician profile
Brittany E Dickert
NPI 1598165474
$16,077.05
in general payments reported to CMS, 2019-2025
43 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,734 · 2022: $3,316 · 2023: $3,783 · 2024: $3,788 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,948 · Education: $79.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,947.77 |
| Education | $79.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,669.58 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,820.44 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,289.23 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,169.65 | 2021-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $961.14 | 2021-2025 | |
| Genzyme Corporation | $759.54 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $562.24 | 2022-2025 | Dupixent |
| Amgen INC. | $490.69 | 2021-2023 | Amjevita, Avsola |
| Intercept Pharmaceuticals, INC. | $468.66 | 2021-2025 | Ocaliva |
| Qol Medical, LLC | $464.70 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $379.61 | 2021-2025 | |
| Celgene Corporation | $356.34 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $350.19 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $343.87 | 2021-2024 | Dificid, Zinplava |
| Redhill Biopharma INC. | $321.01 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $216.79 | 2021-2024 | Injectafer |
| Celltrion USA INC. | $212.50 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $196.85 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $189.97 | 2024-2025 | Resmetirom, Rezdiffra |
| Pharmacosmos Therapeutics INC. | $185.32 | 2021-2024 | Monoferric |
| Alnylam Pharmaceuticals INC. | $185.26 | 2021-2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $179.21 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $175.42 | 2021-2024 | Linzess |
| Fresenius Kabi USA, LLC | $175.35 | 2023-2024 | Idacio |
| Organon LLC | $134.41 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $111.16 | 2021-2023 | Rebyota |
| Braintree Laboratories, INC. | $100.71 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $100.59 | 2021-2023 | |
| Lilly USA, LLC | $69.16 | 2025 | Omvoh |
| Endo Pharmaceuticals INC. | $61.10 | 2021 | |
| Aimmune Therapeutics, INC. | $60.42 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.26 | 2023-2024 | Cyltezo |
| Currax Pharmaceuticals LLC | $39.28 | 2021-2022 | |
| Intra-Sana Laboratories | $38.53 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Digestive Care, INC. | $35.95 | 2024 | Pertzye |
| Medtronic, INC. | $26.62 | 2024 | |
| Enterra Medical, INC. | $23.25 | 2024 | |
| Biocon Biologics INC | $22.50 | 2024 | Hulio |
| Cumberland Pharmaceuticals, INC. | $22.43 | 2022 | |
| Mirum Pharmaceuticals, INC. | $17.85 | 2025 | Livmarli, Chenodal, Cholbam |
| Pharming Healthcare, INC. | $16.71 | 2023 | Ruconest |
| Angiodynamics, INC. | $12.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Dickert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.